Marker Therapeutics Competitors and Similar CompaniesClear all
Marker Therapeutics's competitors and similar companies include Sellas Life Sciences, ImmunoCellular Therapeutics, Celldex Therapeutics and Advaxis.
 Marker Therapeutics Marker Therapeutics is a biopharmaceutical company engaged in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection. |  Sellas Life Sciences SELLAS Life Sciences is a clinical biopharmaceutical company focused on the development of cancer immunotherapies. |  ImmunoCellular Therapeutics ImmunoCellular Therapeutics is a clinical-stage biotechnology company developing immune-based therapies for the treatment of various cancers. |  Celldex Therapeutics Celldex Therapeutics (formerly Avant Immunotherapeutics) is a biopharmaceutical company that specializes in monoclonal and bispecific antibodies development. | ||
Founding Date | Founding Date 2018 | Founding Date 2006 | Founding Date 2006 | Founding Date 1983 | Founding Date 2002 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Houston, US HQ | Locations New York, US HQ New York, US | Locations Calabasas, US HQ | Locations Hampton, US HQ Fall River, US Needham, US New Haven, US | Locations Princeton, US HQ |
Employees | Employees 888% decrease | Employees 538% decrease | Employees 357% decrease | Employees 1608% increase | Employees 3540% decrease |
Valuation ($) | Valuation ($) 36.5 m | Valuation ($) 79.1 m | Valuation ($) 15.9 m | Valuation ($) 1.9 b | Valuation ($) 2.4 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $3.5m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $1.5m (FY, 2025) | Revenue (est.) $13k (FY, 2023) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $200k (FY, 2025) | Cost of goods $13k (FY, 2023) |
Net income | Net income ($12.2m) (FY, 2025) | Net income ($26.9m) (FY, 2025) | Net income ($14.3m) (FY, 2017) | Net income ($258.8m) (FY, 2025) | Net income ($48.1m) (FY, 2023) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 32.5m | Total funding raised $ 2m | Total funding raised $ 50.5m |
For sources of this data, please see the company profile
View Company Profiles
Sellas Life Sciences
HQ
New York, US
Employees
5↓ 38% decrease
SELLAS Life Sciences is a clinical biopharmaceutical company focused on the development of cancer immunotherapies.
View companyImmunoCellular Therapeutics
HQ
Calabasas, US
Employees
3
ImmunoCellular Therapeutics is a clinical-stage biotechnology company developing immune-based therapies for the treatment of various cancers.
View companyCelldex Therapeutics
HQ
Hampton, US
Employees
160↑ 8% increase
Celldex Therapeutics (formerly Avant Immunotherapeutics) is a biopharmaceutical company that specializes in monoclonal and bispecific antibodies development.
View company
Advaxis
HQ
Princeton, US
Employees
35↓ 40% decrease
Advaxis is a biotechnology company developing the next generation of cancer immunotherapies.
View company